Novo Nordisk's Wegovy Pill Dominates New Oral Obesity Prescriptions, Boosting Company Guidance
Trendline

Novo Nordisk's Wegovy Pill Dominates New Oral Obesity Prescriptions, Boosting Company Guidance

What's Happening? Novo Nordisk's Wegovy pill has captured a significant share of the oral GLP-1 weight-loss treatment market. In the third quarter, the company estimates that its pill accounted for 80% of new patients initiating oral GLP-1 weight-loss treatments. This success follows an earlier 'flu
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.